The SIX1-EYA transcriptional complex as a therapeutic target in cancer

MA Blevins, CG Towers, AN Patrick… - Expert opinion on …, 2015 - Taylor & Francis
MA Blevins, CG Towers, AN Patrick, R Zhao, HL Ford
Expert opinion on therapeutic targets, 2015Taylor & Francis
Introduction: The SIX homeodomain proteins and the eyes absent (EYA) family of co-
activators form a bipartite transcription factor complex that promotes the proliferation and
survival of progenitor cells during organogenesis and is down-regulated in most adult
tissues. Abnormal over-expression of SIX1 and EYA in adult tissue is associated with the
initiation and progression of diverse tumor types. Importantly, SIX1 and EYA are often co-
overexpressed in tumors, and the SIX1-EYA2 interaction has been shown to be critical for …
Introduction: The SIX homeodomain proteins and the eyes absent (EYA) family of co-activators form a bipartite transcription factor complex that promotes the proliferation and survival of progenitor cells during organogenesis and is down-regulated in most adult tissues. Abnormal over-expression of SIX1 and EYA in adult tissue is associated with the initiation and progression of diverse tumor types. Importantly, SIX1 and EYA are often co-overexpressed in tumors, and the SIX1-EYA2 interaction has been shown to be critical for metastasis in a breast cancer model. The EYA proteins also contain protein tyrosine phosphatase activity, which plays an important role in breast cancer growth and metastasis as well as directing cells to the repair pathway upon DNA damage.
Areas covered: This review provides a summary of the SIX1/EYA complex as it relates to development and disease and the current efforts to therapeutically target this complex.
Expert opinion: Recently, there have been an increasing number of studies suggesting that targeting the SIX1/EYA transcriptional complex will potently inhibit tumor progression. Although current attempts to develop inhibitors targeting this complex are still in the early stages, continued efforts toward developing better compounds may ultimately result in effective anti-cancer therapies.
Taylor & Francis Online